""

about | Maps & Directions | contact | admissions | faculty | alumni & development | library | Tech Support Center | dean's office | Policies & Procedures

Temple Med News Temple Med News Temple Med News

OFFICE OF news communications

Latest News and Press Releases

Arthur M. Feldman, MD, PhD, Receives Lifetime Achievement Award from the Heart Failure Society of America

September 23, 2013

 

Arthur M. Feldman, MD, PhDArthur M. Feldman, MD, PhD, Executive Dean of Temple University School of Medicine and Chief Academic Officer of Temple University Health System, has received a Lifetime Achievement Award from the Heart Failure Society of America. Dr. Feldman received the award at its 17th annual meeting, held September 23 in Orlando, Florida.

 

Dr. Feldman is a renowned cardiovascular researcher who has led many clinical trials, and his work on the molecular biology of heart failure has been published in over 250 peer-reviewed articles. As past president of the Heart Failure Society of America, he developed and implemented Heart Failure Awareness week, which is now recognized across the United States and Europe.

 

"We are delighted to honor Dr. Art Feldman with this year's lifetime achievement award," said Thomas Force, MD, President of the Heart Failure Society of America. "Art is a distinguished clinician and researcher, and he has contributed a great deal to the field of heart failure and to the Heart Failure Society of America."

 

"I'm honored to receive this prestigious award from the Society," said Dr. Feldman. "I know first-hand the dedication and caliber of the members of this outstanding organization, and to receive this recognition from such a remarkable group is a humbling experience."

 

After receiving his B.A. degree from Gettysburg College, and M.S. and Ph.D. degrees from the University of Maryland, Dr. Feldman served as a post-doctoral fellow in physiology at The Johns Hopkins University School of Medicine. He earned his medical degree from the Louisiana State University School of Medicine and then returned to Johns Hopkins where he served as an intern, resident, and cardiology fellow. After joining the faculty in 1985, he was named director of the Heart Failure Research Program at Johns Hopkins.

 

In 1994, Dr. Feldman joined the faculty at the University of Pittsburgh School of Medicine as the Harry S. Tack Professor of Medicine, Chief of the Division of Cardiology, and Director of the Cardiovascular Institute. In 2002, Dr. Feldman was named the Magee Professor of Medicine and Chairman of the Department of Medicine at Jefferson Medical College in Philadelphia. In September 2011, Dr. Feldman was named Executive Dean of Temple University School of Medicine and Chief Academic Officer of Temple University Health System.

 

Dr. Feldman is a past president of the Heart Failure Society of America and of the Association of Professors of Cardiology. He is the current and founding editor-in-chief of Clinical and Translational Science. He has received numerous honors including election to Alpha Omega Alpha, the Association of University Cardiologists, the American Society for Clinical Investigation, and the Association of American Physicians.

 

His NIH-funded research has focused on the molecular pathobiology of heart failure. Dr. Feldman's lab was the first to recognize the role of G proteins, pro-inflammatory cytokines and vasopressin receptors in the development of the heart failure phenotype. He has translated his basic science work to the clinical arena, chairing the steering committees of numerous multi-center clinical trials, and his research in the molecular biology of heart failure has been published in over 250 peer-reviewed articles.

 

He is the editor of two texts: Heart Failure: Pharmacologic Management and Heart Failure: Device Management. Most recently, he published Pursuing Excellence in Healthcare: Preserving America’s Academic Medical Centers and Understanding Health Care Reform – Bridging the Gap between Myth and Reality. In addition, he was a co-founder and member of the Board of Directors of Cardiokine, Inc., a biotechnology firm.